HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA. KEYTRUDA® (pembrolizumab) for injec

First Page		Document Content
Date: 2014-09-04 16:42:45 Prednisone Prodrugs Adverse effect Adverse effects of fluoroquinolones Anakinra Medicine Health Glucocorticoids		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA. KEYTRUDA® (pembrolizumab) for injec Add to Reading List Source URL: www.merck.com Download Document from Source Website File Size: 196,80 KB Share Document on Facebook

	EAP Reimbursement Criteria for Frequently Requested Drugs DocID: 1rhhE - View Document
	UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol DocID: 1rakB - View Document
	RHEUMATOLOGY Rheumatology 2011;50:iv5iv9 doi:rheumatology/ker241 Indirect and mixed treatment comparisons in arthritis DocID: 1pLt5 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing information for GILOTRIF. ® DocID: 1oOLG - View Document
	------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme DocID: 1m0Le - View Document